Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Pfizer Inc. Discovered Breakthrough Respiratory Syncytial Virus (RSV)

Pfizer Inc, discovered breakthrough respiratory syncytial virus (RSV) vaccine candidate, PF-06928316 or RSVpreF for the treatment of lower respiratory tract illness in infants from birth up to age of six months by active immunisation of pregnant women.

Once approved, the vaccine has the potential as the first maternal immunisation vaccine candidate in protecting infants in their vulnerable first months of life from disease caused by this highly-contagious virus.

After this discovery, Pfizer tested numerous versions of the viral protein, and identified those that elicited a strong anti-viral immune response in pre-clinical evaluation. The vaccine candidate is composed of two preF proteins selected to optimise protection against RSV A and B and is currently being evaluated in ongoing late-stage human trials.

RSV is a contagious virus causing respiratory illness. It mainly affects the lungs and breathing passages of infected individual, resulting in life-threatening for young infants, the immunocompromised, and older adults.

In US, every year approximately 2.1 million outpatient visits and about 58,000 hospitalisations occur among children who are younger than five years old. Moreover, nearly 177,000 hospitalisations and 14,000 deaths are caused due to RVS infections among older patients. Currently, no approved vaccines are in consideration to prevent RSV and the medical community can only only supportive care for those with the illness.

US Food and Drug Administration (FDA) has granted breakthrough designation for respiratory syncytial virus (RSV) vaccine candidate, PF-06928316 or RSVpreF, for prevention of RSV-associated lower respiratory tract illness in infants.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024